MO
GILD icon

McMillan Office’s Gilead Sciences GILD Stock Holding History

McMillan Office’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Hold
2,540
– – 0.04% 154
2026
Q1 		$354K Hold
2,540
– – 0.05% 141
2025
Q4 		$312K Buy
+2,540
New +$309K 0.04% 153

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

McMillan Office's GILD Position: Q2 2026 in Review

McMillan Office held its Gilead Sciences (GILD) position steady in Q2 2026 at 2,540 shares worth $321K. The position accounts for 0.04% of the portfolio, ranked #154.

McMillan Office first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $354K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • McMillan Office held 2,540 shares of Gilead Sciences worth $321K as of Q2 2026.
  • McMillan Office left its Gilead Sciences share count unchanged in Q2 2026.
  • Gilead Sciences made up 0.04% of McMillan Office's portfolio in Q2 2026, its #154 holding.
  • McMillan Office first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • McMillan Office's Gilead Sciences position peaked at $354K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.